➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Express Scripts
McKinsey
Boehringer Ingelheim
Johnson and Johnson
Baxter

Last Updated: April 18, 2021

DrugPatentWatch Database Preview

ENTECAVIR Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which patents cover Entecavir, and what generic alternatives are available?

Entecavir is a drug marketed by Accord Hlthcare, Amneal Pharms, Aurobindo Pharma Ltd, Breckenridge, Brightgene, Casi Pharms Inc, Cipla, Hetero Labs Ltd V, Mylan, Par Pharm Inc, Pharmadax Inc, Prinston Inc, Sunshine, Teva Pharms Usa, Yaopharma Co Ltd, and Zydus Pharms. and is included in sixteen NDAs.

The generic ingredient in ENTECAVIR is entecavir. There are eighteen drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the entecavir profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Entecavir

A generic version of ENTECAVIR was approved as entecavir by HETERO LABS LTD V on August 21st, 2015.

  Start Trial

Drug patent expirations by year for ENTECAVIR
Drug Prices for ENTECAVIR

See drug prices for ENTECAVIR

Drug Sales Revenue Trends for ENTECAVIR

See drug sales revenues for ENTECAVIR

Recent Clinical Trials for ENTECAVIR

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Ascentage Pharma Group Inc.Phase 2
Sunshine Lake Pharma Co., Ltd.Phase 1/Phase 2
Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical FoundationPhase 4

See all ENTECAVIR clinical trials

Paragraph IV (Patent) Challenges for ENTECAVIR
Tradename Dosage Ingredient NDA Submissiondate
BARACLUDE TABLET;ORAL entecavir 021797 2010-06-14

US Patents and Regulatory Information for ENTECAVIR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Zydus Pharms ENTECAVIR entecavir TABLET;ORAL 206745-002 Jun 23, 2017 AB RX No No   Start Trial   Start Trial   Start Trial
Teva Pharms Usa ENTECAVIR entecavir TABLET;ORAL 202122-002 Aug 26, 2014 DISCN No No   Start Trial   Start Trial   Start Trial
Yaopharma Co Ltd ENTECAVIR entecavir TABLET;ORAL 212201-001 Nov 4, 2019 DISCN No No   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Merck
Express Scripts
Mallinckrodt
Medtronic
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.